S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NYSE:LH

Laboratory Co. of America - LH Stock Forecast, Price & News

$220.68
+0.90 (+0.41%)
(As of 03/28/2023 04:00 PM ET)
Add
Compare
Today's Range
$219.00
$221.64
50-Day Range
$213.32
$257.83
52-Week Range
$200.32
$280.72
Volume
547,799 shs
Average Volume
631,607 shs
Market Capitalization
$19.53 billion
P/E Ratio
15.92
Dividend Yield
1.31%
Price Target
$283.50

Laboratory Co. of America MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
28.7% Upside
$283.50 Price Target
Short Interest
Healthy
1.85% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
1.38mentions of Laboratory Co. of America in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.18 M Sold Last Quarter
Proj. Earnings Growth
9.31%
From $17.18 to $18.78 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.43 out of 5 stars

Medical Sector

7th out of 1,002 stocks

Medical Laboratories Industry

1st out of 26 stocks


LH stock logo

About Laboratory Co. of America (NYSE:LH) Stock

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Receive LH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Laboratory Co. of America and its competitors with MarketBeat's FREE daily newsletter.

LH Stock News Headlines

Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Fall
Earnings Preview: Laboratory Corp
Labcorp beats quarterly profit estimates
LabCorp: Q4 Earnings Snapshot
LabCorp reports 20% drop in COVID test sales in Q4
What's in the Cards for Medtronic (MDT) in Q3 Earnings?
See More Headlines
Receive LH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Laboratory Co. of America and its competitors with MarketBeat's FREE daily newsletter.

LH Company Calendar

Last Earnings
2/16/2023
Ex-Dividend for 3/13 Dividend
2/22/2023
Dividend Payable
3/13/2023
Today
3/28/2023
Next Earnings (Estimated)
4/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
Health Care Services
Sector
Medical
CUSIP
50540R40
Employees
80,000
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$283.50
High Stock Price Forecast
$303.00
Low Stock Price Forecast
$260.00
Forecasted Upside/Downside
+29.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$1.28 billion
Pretax Margin
10.64%

Debt

Sales & Book Value

Annual Sales
$14.88 billion
Cash Flow
$31.04 per share
Book Value
$113.96 per share

Miscellaneous

Free Float
88,226,000
Market Cap
$19.45 billion
Optionable
Optionable
Beta
1.06

Social Links


Key Executives

  • Adam H. Schechter
    Chairman, President & Chief Executive Officer
  • Glenn Andrew EisenbergGlenn Andrew Eisenberg
    Chief Financial Officer & Executive Vice President
  • Lance V. Berberian
    Chief Information & Technology Officer & EVP
  • Brian J. CaveneyBrian J. Caveney
    Chief Medical Officer, EVP & President-Diagnostics
  • Stephen M. Anderson
    Chief Scientific Officer-Covance & Senior VP













LH Stock - Frequently Asked Questions

Should I buy or sell Laboratory Co. of America stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LH shares.
View LH analyst ratings
or view top-rated stocks.

What is Laboratory Co. of America's stock price forecast for 2023?

9 analysts have issued 1-year target prices for Laboratory Co. of America's stock. Their LH share price forecasts range from $260.00 to $303.00. On average, they predict the company's share price to reach $283.50 in the next year. This suggests a possible upside of 29.0% from the stock's current price.
View analysts price targets for LH
or view top-rated stocks among Wall Street analysts.

How have LH shares performed in 2023?

Laboratory Co. of America's stock was trading at $235.48 at the start of the year. Since then, LH stock has decreased by 6.7% and is now trading at $219.78.
View the best growth stocks for 2023 here
.

Are investors shorting Laboratory Co. of America?

Laboratory Co. of America saw a increase in short interest in February. As of February 28th, there was short interest totaling 1,640,000 shares, an increase of 13.1% from the February 13th total of 1,450,000 shares. Based on an average daily volume of 631,700 shares, the days-to-cover ratio is currently 2.6 days. Currently, 1.9% of the company's shares are sold short.
View Laboratory Co. of America's Short Interest
.

When is Laboratory Co. of America's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our LH earnings forecast
.

How were Laboratory Co. of America's earnings last quarter?

Laboratory Co. of America Holdings (NYSE:LH) posted its quarterly earnings data on Thursday, February, 16th. The medical research company reported $4.14 earnings per share for the quarter, topping the consensus estimate of $4.06 by $0.08. The medical research company had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.74 billion. Laboratory Co. of America had a trailing twelve-month return on equity of 17.68% and a net margin of 8.60%. The firm's quarterly revenue was down 9.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.77 earnings per share.
Read the conference call transcript
.

How often does Laboratory Co. of America pay dividends? What is the dividend yield for Laboratory Co. of America?

Laboratory Co. of America declared a quarterly dividend on Thursday, January 12th. Stockholders of record on Thursday, February 23rd will be given a dividend of $0.72 per share on Monday, March 13th. This represents a $2.88 dividend on an annualized basis and a yield of 1.31%. The ex-dividend date is Wednesday, February 22nd.
Read our dividend analysis for LH
.

Is Laboratory Co. of America a good dividend stock?

Laboratory Co. of America (NYSE:LH) pays an annual dividend of $2.88 per share and currently has a dividend yield of 1.32%. The dividend payout ratio is 20.78%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LH will have a dividend payout ratio of 15.34% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LH.

What guidance has Laboratory Co. of America issued on next quarter's earnings?

Laboratory Co. of America updated its FY 2023 earnings guidance on Monday, February, 20th. The company provided earnings per share guidance of $16.00-$18.00 for the period, compared to the consensus EPS estimate of $17.65. The company issued revenue guidance of $15.03 billion-$15.47 billion, compared to the consensus revenue estimate of $15.01 billion.

What is Adam Schechter's approval rating as Laboratory Co. of America's CEO?

143 employees have rated Laboratory Co. of America Chief Executive Officer Adam Schechter on Glassdoor.com. Adam Schechter has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Laboratory Co. of America own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Laboratory Co. of America investors own include Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Pfizer (PFE), Johnson & Johnson (JNJ), NVIDIA (NVDA), Abbott Laboratories (abt), AbbVie (ABBV), Alibaba Group (BABA) and Amgen (AMGN).

What is Laboratory Co. of America's stock symbol?

Laboratory Co. of America trades on the New York Stock Exchange (NYSE) under the ticker symbol "LH."

Who are Laboratory Co. of America's major shareholders?

Laboratory Co. of America's stock is owned by a number of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (2.05%), Bank of America Corp DE (1.75%), Lazard Asset Management LLC (1.73%), Dimensional Fund Advisors LP (1.65%), Morgan Stanley (1.49%) and Norges Bank (1.05%). Insiders that own company stock include Amy B Summy, Brian J Caveney, Der Vaart Sandra D Van, Dwight Gary Gilliland, Glenn A Eisenberg, Jean-Luc Belingard, Mark S Schroeder, Paul R Kirchgraber, Peter J Wilkinson, Peter M Neupert and R Sanders Williams.
View institutional ownership trends
.

How do I buy shares of Laboratory Co. of America?

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Laboratory Co. of America's stock price today?

One share of LH stock can currently be purchased for approximately $219.78.

How much money does Laboratory Co. of America make?

Laboratory Co. of America (NYSE:LH) has a market capitalization of $19.45 billion and generates $14.88 billion in revenue each year. The medical research company earns $1.28 billion in net income (profit) each year or $13.86 on an earnings per share basis.

How many employees does Laboratory Co. of America have?

The company employs 80,000 workers across the globe.

Does Laboratory Co. of America have any subsidiaries?
The following companies are subsidiares of Laboratory Co. of America: 1957285 Ontario Inc. dba Quality Underwriting Services, 2089729 Ontario Inc., 2248848 Ontario Inc., 3065619 Nova Scotia Company, 3257959 Nova Scotia Company, 8165335 Canada Inc., 8348596 Canada Inc., 896988 Ontario Limited, 9279-3280 Quebec Inc., Accupath Diagnostic Laboratories Inc., Assets of Pathology Inc, Beacon LBS IPA Inc., Beacon Laboratory Benefit Solutions Inc., CannAmm GP Inc., CannAmm Limited Partnership, Center for Disease Detection International, Center for Disease Detection LLC, Centrex Clinical Laboratories Inc., Chiltern, Clearstone Central Laboratories (U.S.) Inc., Clearstone Holdings (International) Ltd., Clinical Outreach Laboratory Services, Clipper Holdings Inc., Colorado Coagulation Consultants Inc., Colorado Laboratory Services LLC, Correlagen Diagnostics Inc., Covance Inc., Curalab Inc., Cytometry Associates Inc., Czura Thornton (Hong Kong) Limited, DCL Acquisition Inc., DCL Medical Laboratories LLC, DCL Sub LLC, DIANON Systems Inc., DL Holdings Limited Partnership, Decision Diagnostics L.L.C. (aka DaVinici/Medicorp LLC), Diagnostic Services Inc., DynaLifeDX, Dynacare - Gamma Laboratory Partnership, Dynacare Company, Dynacare G.P. Inc., Dynacare Holdco LLC, Dynacare Laboratories Inc., Dynacare Laboratories Limited Partnership, Dynacare Northwest Inc., Dynacare Realty Inc., DynalifeDX Infrastructure Inc., Envigo's nonclinical contract research services business, Esoterix Genetic Counseling LLC, Esoterix Genetic Laboratories LLC, Esoterix Inc., Execmed Health Services Inc., FirstSource Laboratory Solutions Inc., GDML Medical Laboratories Inc, Gamma Dynacare Central Medical Laboratories GP Inc., Gamma Dynacare Central Medical Laboratory Limited Partnership, HHLA Lab-In-An-Envelope LLC, Health Testing Centers Inc., Health Trans Services Inc., Home Healthcare Laboratory of America LLC, IDX Pathology Inc., Impact Genetics Corporation, Impact Genetics Inc., Kaleida LabCorp LLC, Lab Delivery Service of New York City Inc., LabCorp BVBA, LabCorp Belgium Holdings Inc., LabCorp Central Laboratories (Canada) Inc., LabCorp Central Laboratories (China) Inc., LabCorp Colorado Inc., LabCorp Development Company, LabCorp Employer Services Inc., LabCorp Health System Diagnostics LLC, LabCorp Indiana Inc., LabCorp Japan G.K., LabCorp Limited, LabCorp Michigan Inc., LabCorp Nebraska Inc., LabCorp Neon Ltd., LabCorp Neon Switzerland S.à.r.l., LabCorp Specialty Testing Billing Service Inc., LabCorp Specialty Testing Group Inc., LabCorp Staffing Solutions Inc., LabCorp Tennessee LLC, LabCorp UK Holdings Ltd., LabWest Inc., Laboratoire Bio-Medic Inc., Laboratory Corporation of America, Lifecodes Corporation, LipoScience Inc., Litholink Corporation, MEDTOX Scientific Inc., MNG Laboratories, MedAxio Insurance Medical Services GP Inc., MedAxio Insurance Medical Services LP, Medical Neurogenitics LLC, Medtox Diagnostics Inc., Medtox Laboratories Inc., Monogram Biosciences Inc., Monogram Biosciences UK Limited, Myriad Autoimmune’s Vectra Testing Business, NWT Inc., National Genetics Institute, New Brighton Business Center LLC, New Imaging Diagnostics LLC, New Molecular Diagnostics Ventures LLC, Orchid Cellmark ULC, Ovia Health, PA Labs Inc., Paclab LLC, Path Lab Incorporated, Pathology Associates Medical Lab LLC, Pee Dee Pathology Associates Inc., Personal Genome Diagnostics Inc., Persys Technology Inc., Pixel by LabCorp, Princeton Diagnostic Laboratories of America Inc., Protedyne Corporation, SW/DL LLC, Saint Josephs-PAML LLC, Sequenom Biosciences (India) Pvt. Ltd., Sequenom Inc, Sequenom Inc., Tandem Labs Inc., Toxikon Corporation, Tri-Cities Laboratory LLC, Viro-Med Laboratories Inc., Visiun, and Yakima Medical Arts Inc..
Read More
How can I contact Laboratory Co. of America?

Laboratory Co. of America's mailing address is 358 South Main Street, BURLINGTON NC, 27215. The official website for the company is www.labcorp.com. The medical research company can be reached via phone at (336) 229-1127, via email at investor@labcorp.com, or via fax at 336-513-4510.

This page (NYSE:LH) was last updated on 3/28/2023 by MarketBeat.com Staff